The Chronic Obstructive Pulmonary Disease (COPD) market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Obstructive Pulmonary Disease (COPD): An Overview
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), Chronic obstructive pulmonary disease (COPD) is a common disease characterized by progressive airflow limitation and tissue destruction. It is associated with structural lung changes due to chronic inflammation from prolonged exposure to noxious particles or gases, most commonly cigarette smoke. Other causes may include second-hand smoke, environmental and occupational exposures, and alpha-1 antitrypsin deficiency (AATD).
COPD is most commonly of two types: chronic bronchitis and emphysema. Chronic bronchitis involves inflammation and irritation of the airways, which leads to the thickening of the lining of the airways. Emphysema involves the shattering of the walls of the alveolar sacs, which reduces the amount of gas exchange in the lungs.
Chronic Obstructive Pulmonary Disease (COPD) Market Key Facts
The Global Burden of Disease Study had reported a prevalence of 251 million COPD cases globally in 2016.
COPD is primarily present in smokers and those >40 years. Prevalence increases with age, and it is currently the third most common cause of morbidity and mortality worldwide. In 2015, the prevalence of COPD was 174 million, and there were approximately 3.2 million deaths due to COPD worldwide. However, the prevalence is most likely underestimated due to the underdiagnosis of COPD.
Epidemiological studies show that between 20% and 40% of all COPD patients worldwide are nonsmokers; thus, although smoking is the main COPD risk factor, other conditions have to be considered as well (Salvi et. al., n.d.).
As per the British Lung Foundation (n.d.) approximately one in five people in the UK develop asthma, COPD, or another long-term respiratory illness. COPD is the second most common lung disease in the UK after asthma in terms of diagnosed cases.
Chronic Obstructive Pulmonary Disease (COPD) market size is expected to grow in the coming years owing to the advances in the characterization of the disease, treatment options, imaging modalities, and a better understanding of the comorbidities, launch of the emerging therapies, among others.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Chronic Obstructive Pulmonary Disease market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Chronic Obstructive Pulmonary Disease market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Segmentation
Prevalent cases of COPD
Age-specific Prevalent Cases of COPD
Gender-specific Prevalent Cases of COPD
Subtype-specific Prevalent Cases of COPD
Diagnosed and treatable cases of COPD
Severity-specific Prevalent Cases of COPD
Chronic Obstructive Pulmonary Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Obstructive Pulmonary Disease market or expected to get launched during the study period. The analysis covers Chronic Obstructive Pulmonary Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Obstructive Pulmonary Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Analysis
Globally, several major players are involved in developing therapies for chronic obstructive pulmonary disease (COPD). The expected launch of therapies is expected to change the treatment landscape of COPD in the upcoming years.
Some of the key companies in the Chronic Obstructive Pulmonary Disease (COPD) Market include:
And many others
Chronic Obstructive Pulmonary Disease (COPD) Therapies covered in the report include:
And many more
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Obstructive Pulmonary Disease Competitive Intelligence Analysis
4. Chronic Obstructive Pulmonary Disease Market Overview at a Glance
5. Chronic Obstructive Pulmonary Disease Disease Background and Overview
6. Chronic Obstructive Pulmonary Disease Patient Journey
7. Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population
8. Chronic Obstructive Pulmonary Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Obstructive Pulmonary Disease Unmet Needs
10. Key Endpoints of Chronic Obstructive Pulmonary Disease Treatment
11. Chronic Obstructive Pulmonary Disease Marketed Products
12. Chronic Obstructive Pulmonary Disease Emerging Therapies
13. Chronic Obstructive Pulmonary Disease Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Obstructive Pulmonary Disease Market Outlook (7 major markets)
16. Chronic Obstructive Pulmonary Disease Access and Reimbursement Overview
17. KOL Views on the Chronic Obstructive Pulmonary Disease Market.
18. Chronic Obstructive Pulmonary Disease Market Drivers
19. Chronic Obstructive Pulmonary Disease Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Radiofrequency Ablation Devices Market
“Radiofrequency Ablation Devices Market” research report provides comprehensive insights into the Radiofrequency Ablation Devices market size, share, trends as well as the key companies and emerging products in the market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States